Ruxolitinib for myelofibrosis-An update of its clinical effects

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 6, 2013, Pages 638-645

  Kantarjian, Hagop M ^a   Silver, Richard T ^b   Komrokji, Rami S ^c   Mesa, Ruben A ^d   Tacke, Roland ^e   Harrison, Claire N ^f  

^a UNIVERSITY OF TEXAS   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e Evidence Scientific Solutions   (United States)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

JAK inhibitor; Myeloproliferative neoplasm; Overall survival; Ruxolitinib; Splenomegaly

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2; PLACEBO; RUXOLITINIB;

ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FOLLOW UP; GENE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JANUS KINASE 2 GENE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; SPLEEN SIZE; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

JAK INHIBITOR; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; RUXOLITINIB; SPLENOMEGALY;

HUMANS; JANUS KINASES; PLATELET COUNT; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; TREATMENT OUTCOME;

EID: 84887870449     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.09.006     Document Type: Review

References (49)

1. R.A. Mesa, A. Green, and G. Barosi MPN-associated myelofibrosis (MPN-MF) Leuk Res 35 2011 12 13
2. G. Barosi, R.A. Mesa, and J. Thiele Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment Leukemia 22 2008 437 438
3. S.A. Gregory, R.A. Mesa, R. Hoffman, and J.M. Shammo Clinical and laboratory features of myelofibrosis and limitations of current therapies Clin Adv Hematol Oncol 9 2011 1 16
4. A. Tefferi, J. Thiele, and A. Orazi Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 2007 1092 1097
5. O.I. Abdel-Wahab, and R.L. Levine Primary myelofibrosis: update on definition, pathogenesis, and treatment Annu Rev Med 60 2009 233 245
6. A. Tefferi Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management Am J Hematol 86 2011 1017 1026
7. Mehta J, Wang H, Iqbal SU, Mesa R: Epidemiology of myeloproliferative neoplasms (MPN) in the United States [e-pub ahead of print]. Leuk Lymphoma. http://10.3109/10428194.2013.813500. Accessed: April 15, 2013.
8. F. Cervantes, B. Dupriez, and A. Pereira New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2009 2895 2901
9. A. Tefferi, T.L. Lasho, and T. Jimma One thousand patients with primary myelofibrosis: the Mayo Clinic experience Mayo Clin Proc 87 2012 25 33
10. A. Quintas-Cardama, H. Kantarjian, J. Cortes, and S. Verstovsek Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond Nat Rev Drug Discov 10 2011 127 140
11. N.C. Cross Genetic and epigenetic complexity in myeloproliferative neoplasms Hematology Am Soc Hematol Educ Program 2011 2011 208 214
12. W. Vainchenker, F. Delhommeau, S.N. Constantinescu, and O.A. Bernard New mutations and pathogenesis of myeloproliferative neoplasms Blood 118 2011 1723 1735
13. A.C. Ward, I. Touw, and A. Yoshimura The JAK-STAT pathway in normal and perturbed hematopoiesis Blood 95 2000 19 25
14. J. Mascarenhas, N. Roper, P. Chaurasia, and R. Hoffman Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies Clin Epigenetics 2 2011 197 212
15. A. Tefferi Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 Leukemia 24 2010 1128 1138
16. F. Passamonti, E. Rumi, and D. Pietra A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications Leukemia 24 2010 1574 1579
17. J. Zhou, Y. Ye, and S. Zeng Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts PLoS One 8 2013 e57856
18. R.T. Silver, K. Vandris, and Y.L. Wang JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy Leuk Res 35 2011 177 182
19. S. Verstovsek, H. Kantarjian, and R.A. Mesa Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 363 2010 1117 1127
20. T. Barbui, G. Barosi, and G. Birgegard Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet J Clin Oncol 29 2011 761 770
21. F. Passamonti, F. Cervantes, and A.M. Vannucchi A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood 115 2010 1703 1708
22. N. Gangat, D. Caramazza, and R. Vaidya DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status J Clin Oncol 29 2011 392 397
23. A.M. Vannucchi Management of myelofibrosis Hematology Am Soc Hematol Educ Program 2011 2011 222 230
24. S. Verstovsek, R.A. Mesa, and J. Gotlib A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
25. C. Harrison, J.J. Kiladjian, and H.K. Al-Ali JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
26. C.N. Harrison, R.A. Mesa, and J.J. Kiladjian Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy Br J Haematol 162 2013 229 239
27. S. Verstovsek, R.A. Mesa, and J. Gotlib Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I ASH Annual Meeting Abstracts 120 2012 800
28. F. Cervantes, J.-J. Kiladjian, and D. Niederwieser Long-term safety, efficacy, and survival Findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) ASH Annual Meeting Abstracts 120 2012 801
29. F. Cervantes, R. Mesa, and C. Harrison JAK inhibitors: beyond spleen and symptoms? Haematologica 98 2013 160 162
30. R.A. Mesa, S. Schwager, and J. Huang Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the pre JAK2 Inhibitor era ASH Annual Meeting Abstracts 114 2009 3918
31. N. Sulai, B. Mengistu, and N. Gangat Decreased levels of total or HDL cholesterol in primary myelofibrosis are associated with shortened survival: DIPSS-Plus independent prognostic value ASH Annual Meeting Abstracts 120 2012 2851
32. R.A. Mesa, S. Verstovsek, and V. Gupta Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I ASH Annual Meeting Abstracts 120 2012 1733
33. S. Verstovsek, R.A. Mesa, and J. Gotlib The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis Br J Haematol 161 2013 508 516
34. C.N. Harrison, J.-J. Kiladjian, and H. Gisslinger Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study ASH Annual Meeting Abstracts 118 2011 279
35. R.A. Mesa, J. Gotlib, and V. Gupta Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial J Clin Oncol 31 2013 1285 1292
36. R.A. Mesa, J. Gotlib, and H.M. Kantarjian Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms ASH Annual Meeting Abstracts 120 2012 1727
37. S. Verstovsek, J.-J. Kiladjian, and R.A. Mesa Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials ASH Annual Meeting Abstracts 120 2012 2847
38. Mesa RA, Verstovsek S, Atallah E, et al. Relationship between ruxolitinib dose and improvements in spleen volume and symptoms in patients with myelofibrosis: results from COMFORT-I. Poster presented at: 8th Annual Hematologic Malignancies Conference; October 10-14, 2012; Houston, TX.
39. Verstovsek S, Quintas-Cardama A, Mesa RA, et al. Management of cytopenias with ruxolitinib treatment in patients with myelofibrosis. Poster presented at: 8th Annual Hematologic Malignancies Conference; October 10-14, 2012; Houston, TX.
40. A. Tefferi, and A. Pardanani Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis Mayo Clin Proc 86 2011 1188 1191
41. Jakafi (ruxolitinib) tablets [prescribing information]. Wilmington, DE: Incyte Corporation; 2013. Available at: http://www.incyte.com/sites/default/ files/Jakafi-PI.pdf. Accessed: June 15, 2013.
42. S. Verstovsek, R.A. Mesa, and J.R. Gotlib Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy J Clin Oncol 30 suppl 2012 abstract 6624
43. 9/L): a comparison to patients with normal or high starting platelet counts ASH Annual Meeting Abstracts 120 2012 176
44. 9/L ASH Annual Meeting Abstracts 120 2012 177
45. H. Geyer, K. Cannon, and E. Knight Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience Following FDA Approval Leuk Lymphoma 2013 10.3109/10428194.2013.789507
46. H. Nguyen, A. Pham, and C. Perkins FDA-approved ruxolitinib in patients with myelofibrosis: the Stanford experience ASH Annual Meeting Abstracts 120 2012 1747
47. A. Andreoli, J. Rey, and C. Dauriac Ruxolitinib therapy in myelofibrosis: Analysis of 241 patients treated in compassionate use (French "ATU" program) by the French Intergroup of Myeloproliferative Neoplasms (FIM) ASH Annual Meeting Abstracts 120 2012 2841
48. G. Barosi, M. Agarwal, and S. Zweegman An individual patient supply program for ruxolitinib for the treatment of patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) ASH Annual Meeting Abstracts 120 2012 2844
49. Press Release: Incyte Corporation: Jakafi (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information. Available at: http://finance.yahoo.com/news/jakafi-ruxolitinib-prescribing- information-updated-211500260.html. Accessed on: June 15, 2013.